Last reviewed · How we verify
NCT05120362
A Study to Evaluate JAK Inhibitor Cream in EGFR-inhibitor-induced Skin Rash
NA trial testing Cream containing JAK Inhibitor in Acneiform Eruptions in 12 participants. Status unknown.
31 March 2023
Quick facts
| Lead sponsor | Shanghai East Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 3 November 2021 |
| Primary completion | 31 March 2023 |
| Estimated completion | 30 April 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Cream containing JAK Inhibitor — full drug profile →
Conditions studied
- Acneiform Eruptions — all drugs for Acneiform Eruptions →
Sponsor
Shanghai East Hospital
Who can join
18 and older, any sex, with Acneiform Eruptions. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Epidermal growth factor receptor inhibitors (EGFRIs) are widely used targeted agents that have been approved for the treatment of various tumor types. In some clinical studies with EGFRIs, the incidence of dermatology AE, the skin rash, is reportedly as high as 95%, which profoundly impact the patients' quality of life. However no treament for onset skin rash has been approved to be effective by any clinical trial yet. Janus kinase (JAK) inhibitor, has been approved for or studied in a variety of skin conditions such as alopecia areata, atopic dermatitis, and psoriasis. Thus the investigators intend to evaluate the efficacy and safety of JAK inhibitor cream for the treatment of EGFRIs-induced skin rash in cancer patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Topical JAK inhibition ameliorates EGFR inhibitor-induced rash in rodents and humans.
You Q, Chen L, Li S, Liu M, et al · · 2024 · cited 8× · PMID 38896602 · DOI 10.1126/scitranslmed.abq7074
Verify or expand the search:
- PubMed search for NCT05120362
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Shanghai East Hospital trials
Trials by the same sponsor.
- NCT07519161 — Pharmacological Intervention to Prevent NOAF After TAVR · NA · not yet recruiting
- NCT07516223 — MRI-Assisted Guidance for Non-Essential Tissue Sampling · NA · not yet recruiting
- NCT07279259 — Thrombolysis in Early Acute Ischemic Stroke Trial-Blood Pressure Management · Phase 2 · recruiting
- NCT07294495 — Effect of Henagliflozin on Myocardial Fibrosis in Non-Obstructive HCM: A Randomized, Double-Blind, Placebo-Controlled Tr · NA · not yet recruiting
- NCT07290816 — Effect of Non-invasive Neuromodulation on the Quality of Intestinal Cleansing · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05120362 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai East Hospital
- Last refreshed: 2 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05120362.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing